Here are relevant reports on : infectious-disease-diagnostics-market
-
US Veterinary Diagnostics Market by Application (Infectious, Bacterial, Endocrine), Technology (Immunodiagnostic, PCR, ELISA, Lateral Flow), Product (Consumables, Instruments), Animal Type (Dog, Cat, Cattle), End User (POC, Veterinary Labs) – Forecast to 2031
The US veterinary diagnostics market, valued at USD2.22 billion in 2025, stood at USD2.41 billion in 2026 and is projected to advance at a resilient CAGR of 9.1% from 2026 to 2031, culminating in a forecasted valuation of USD3.74 billion by the end of the period.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030
The global in vitro diagnostics market, valued at US$101.05billion in 2024, stood at US$109.06 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$157.63 billion by the end of the period. Market growth is primarily fueled by the rising prevalence of chronic and infectious diseases, increasing demand for rapid and accurate diagnostic solutions, and the growing shift toward personalized medicine.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Europe In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Europe in vitro diagnostics (IVD) market, valued at USD 31.43 billion in 2025, stood at USD 33.83 billion in 2026 and is projected to advance at a resilient CAGR of 7.9% from 2026 to 2031, culminating in a forecasted valuation of USD 49.49 billion by the end of the period. Market growth is driven by rising diagnostic test volumes across national healthcare systems, broader adoption of population-based screening programs, and increasing emphasis on standardized disease monitoring.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
US In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
US In Vitro Diagnostics market, valued at USD 37.43 billion in 2025, stood at USD 40.15 billion in 2026 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2031, culminating in a forecasted valuation of USD 57.18 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic and infectious diseases, the increasing demand for early and accurate diagnostic testing, the widespread adoption of advanced molecular diagnostic technologies, the growth in point-of-care testing, and continuous innovations in diagnostic instruments and assays.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Asia Pacific in vitro diagnostics market is valued at an estimated USD 29.27 billion in 2026 and is projected to reach USD 45.11 billion by 2031 at a CAGR of 9.0% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher (US), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., (China)., Siemens Healthineers AG (Germany), bioMérieux (France), Illumina, Inc. (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Forecast to 2030
The global tissue diagnostics market is projected to reach USD 10.86 billion by 2030 from USD 6.74 billion in 2025, at a CAGR of 10.0% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Merck KGAa (Germany), and Agilent Technologies (US).
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Cattle & Porcine/Swine Reproductive Diseases Market by Product (Diagnostics (ELISA, PCR, Rapid Antigen Testing), Pharmaceuticals (Vaccines), Supplements, Animal Type, Disease (BVD, PRRS, Leptospirosis, Brucellosis), End User - Global Forecast to 2029
The global cattle & porcine/swine reproductive diseases market, valued at US$726.9 million in 2023, stood at US$758.2 million in 2024 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2029, culminating in a forecasted valuation of US$975.8 million by the end of the period. Increasing investments, funding, and grants from various governments and organizations to improve animal health, along with a growing number of veterinarians in developing nations, are enhancing the treatment of diseases.
- Published: October 2024
- Price: $ 4950
- TOC Available:
-
Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031
The global autoimmunity diagnostics market, valued at US$5.26 billion in 2024, stood at US$5.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2031, culminating in a forecasted valuation of US$8.98 billion by the end of the period. The autoimmunity diagnostics market is consistently growing, fueled by several key factors. These include the rising prevalence of autoimmune disease, growing awareness about early and accurate diagnosis, increasing research activities, and rapid advancements in diagnostic technologies.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
The Lymphedema Diagnostics Market is expected to grow from USD 24 million in 2019 to USD 35 million by 2024, at a CAGR of 7.4% during the forecast period. The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
- Published: October 2019
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
